Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Clinical trial NCT06179108 · COMPLETED
Trial details
- NCT number
- NCT06179108
- Sponsor
- LB Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-29
- Primary completion
- 2024-12-04
- Enrollment
- 359
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.